Clinical trial · Observational
Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer
NCT01300871CI-TRIAL-00015713terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Poor patient accrual
Summary
Brief summary (as posted)
This is a study to determine the prevalence and severity of alopecia (hair loss) experienced by postmenopausal breast cancer patients receiving endocrine therapy including Tamoxifen, Letrozole (Femara), Exemestane (Aromasin), or Anastrozole (Arimidex).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Postmenopausal Women on Endocrine Therapy
- description
- Postmenopausal women with Breast Cancer that undergo Endocrine Therapy.
Primary outcomes (1)
- measure
- Severity of Alopecia Tool (SALT)
- timeFrame
- 1 year
- description
- The proportion of postmenopausal breast cancer patients on endocrine therapy who experience grade S1 to S5 alopecia as defined by the Severity of Alopecia Tool (SALT).
Secondary outcomes (2)
- measure
- Comparison of Tamoxifen, AI or Tamoxifen plus AI
- timeFrame
- 1 year
- description
- Comparison of the proportion of postmenopausal breast cancer patients treated with Tamoxifen monotherapy, AI monotherapy, or a switch from Tamoxifen to AI who experience alopecia.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Postmenopausal women * Diagnosed with hormone-receptor positive breast cancer * Commenced adjuvant endocrine therapy ≥ 3 months ago, specifically Tamoxifen, Anastrozole, Exemestane, and/or Letrozole * Good command of the English language * Under the care of a medical oncologist at Princess Margaret Hospital Exclusion Criteria: * Previously received chemotherapy * Recurrent and/or metastatic disease * History of endocrine, dermatology, or immune system disorders known to alter hair growth (ie. Hypothyroidism and iron deficiency)
References
Publications (0)
Data not yet available
No reference posted for this study.